Protective effect of SNMC on mice with fulminant liver failure.
- Author:
Li-yan CHEN
1
;
Bao-shan YANG
;
Ying-ji MA
;
Man-ru BI
;
Feng GAO
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Anti-Inflammatory Agents, Non-Steroidal; therapeutic use; Female; Galactosamine; Glycyrrhizic Acid; therapeutic use; Lipopolysaccharides; Liver Failure, Acute; chemically induced; drug therapy; Male; Mice
- From: Chinese Journal of Hepatology 2005;13(3):209-212
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the protective effect of stronger neo-minophagen C (SNMC) on fulminant liver failure (FLF).
METHODSD-Gal N and LPS were injected once into the abdominal cavity of rats to establish an experimental model of FLF. The level of plasma ALT, Alb, TBil, TNFalpha, NO, ET-1, IL-6 and liver histopathology of the rats were examined.
RESULTSIn the D-Gal N and LPS model of FLF, there was an obvious decline of plasma TNFalpha (F = 52.84), NO (F = 15.81), ET-1 (F = 15.68), IL-6 (F = 15.32) and there was less hepatic tissue damage in SNMC-treated groups using different doses (high dose, medium dose, low dose) and at different times (pre-protection, simultaneous protection, post-protection) compared with those not treated with SNMC. These results indicated that SNMC could be used to treat FLF. It was better to use a low dose of SNMC and use it at the same time as inducing the FLF. There were no differences in the results of those treated with SNMC of different dosages and treated at different times.
CONCLUSIONSNMC can decrease the mortality of FLF by preventing hepatocyte apoptosis induced by D-Gal N and LPS and inhibit liver inflammation caused by all kinds of factors.
